Amgen received approval from the FDA for Prolia (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, administered every six months by subcutaneous injection, is the first FDA-approved RANK Ligand inhibitor. The approval is based on a Phase III study in 7,808 postmenopausal women with osteoporosis. Treatment with Prolia resulted in greater bone density, s...